Manfred Bodenlenz
Manfred Bodenlenz publishes mostly in Endocrinology, Diabetes and Metabolism, Immunology and Pharmaceutical Science, on topics such as Advancements in Transdermal Drug Delivery, Diabetes Management and Research and Hyperglycemia and glycemic control in critically ill and hospitalized patients.
- World rank
- #3,119,568 of 7,710,434 ranked researchers
- Rank in Austria
- #18,832 of 43,330
- Works
- 49
- Citations
- 1.4k
- Citations per work
- 29.6
What does Manfred Bodenlenz research?
Manfred Bodenlenz's work is mostly in Medicine (39%), Immunology and Microbiology (12%), Pharmacology, Toxicology and Pharmaceutics (10%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1939.1%
- Medicine1939.1%
- Everything else1530.9%
- Life Sciences1122.5%
- Physical Sciences47.5%
- Engineering47.5%
- 1Endocrinology, Diabetes and Metabolism25% of their works
- 2Immunology12% of their works
- 3Pharmaceutical Science10% of their works
- 4Dermatology9% of their works
- 5Biomedical Engineering8% of their works
- 6Epidemiology5% of their works
Research topics
- Advancements in Transdermal Drug Delivery
- Diabetes Management and Research
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Diabetic Foot Ulcer Assessment and Management
- Adipokines, Inflammation, and Metabolic Diseases
- Pancreatic function and diabetes
Which keywords describe Manfred Bodenlenz's research?
The keywords of their largest research topics: Glycemic Control, Insulin Therapy, Diabetes, Cardiovascular Disease, Diabetes Mellitus, Microneedles, Solid Lipid Nanoparticles and Continuous Glucose Monitoring.
- Pancreatic Islets
- Inflammation
- Foot Ulcers
- Skin Microbiome
- Filaggrin
- Critical Care
- Continuous Glucose Monitoring
- Microneedles
- Cardiovascular Disease
- Insulin Therapy
- Glycemic Control
- Diabetes
- Diabetes Mellitus
- Solid Lipid Nanoparticles
- Hypoglycemia
- Hyperglycemia
- IL-17
- TH17 Cells
- Prevention
- Obesity
- ß-Cell Dysfunction
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Glycemic Control252 topics
- Insulin Therapy252 topics
- Diabetes182 topics
- Cardiovascular Disease172 topics
- Diabetes Mellitus162 topics
- Microneedles141 topic
- Solid Lipid Nanoparticles141 topic
- Continuous Glucose Monitoring131 topic
- Hypoglycemia131 topic
- Critical Care121 topic
- Hyperglycemia121 topic
- Filaggrin91 topic
- IL-1791 topic
- Skin Microbiome91 topic
- TH17 Cells91 topic
- Foot Ulcers51 topic
- Prevention51 topic
- Inflammation41 topic
- Obesity41 topic
- Pancreatic Islets41 topic
- ß-Cell Dysfunction41 topic
Where does Manfred Bodenlenz work?
Manfred Bodenlenz's main affiliation in the publication record is Joanneum Research, Austria.
How many publications and citations does Manfred Bodenlenz have?
OpenAlex counts 49 works and 1,448 citations for Manfred Bodenlenz, an h-index of 17, ranking #3,119,568 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Manfred Bodenlenz. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.